PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED

CoherentMI reports the Clinical Trial Patient Recruitment Services Market valued at US$ 9.4 Billion in 2024, projected to reach US$ 19.1 Billion by 2031, growing at a CAGR of 8.2%. The market is driven by increasing clinical trials and R&D investments in drug development.

Mwango Kashoki, Parexel's SVP, global head of regulatory strategy, discusses FDA's new guidance for multiregional oncology trials, emphasizing the need for diverse patient populations. Companies must plan global oncology programs early, ensuring data applicability to the US population, and consider expanding trial sites to community-based settings for streamlined data capture.

Mwango Kashoki discusses FDA's new guidance for multiregional oncology trials, emphasizing the need for diverse patient populations. The guidance requires proactive planning to ensure data applicability to the US population, considering patient characteristics and healthcare systems. It encourages enrolling foreign participants and diversifying clinical trial sites beyond traditional academic centers, aiming for broader access and representation.

Panthera Biopartners becomes the first UK public or commercial clinical trial organization to join Parexel's Site Alliance Vaccine Network, recognized for exceptional patient recruitment and strong partnership with Parexel. Panthera has been the top global recruiter in four studies and the top UK recruiter in six others, crucial for pharma and CROs. Chris Dodd, Panthera's Chief Commercial Officer, highlights the partnership's potential to increase clinical research in the UK, addressing underrepresentation in clinical trials.

Teri Karcher, Parexel's Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence, has been named to the 2024 PharmaVoice 100 list for her innovative leadership in drug development, significantly enhancing Parexel's site relationships and patient-guided strategies.

DPHARM 2024 focused on innovations in clinical trials, featuring keynotes on ROI, DCTs, AI, and patient perspectives. Panels discussed efficiency, AI use, and ecosystem approaches. Outside-industry speakers offered unique insights. Technologists showcased patient-centric services. Sponsors highlighted innovation and collaboration. DPHARM Idol Disrupt finalists presented disruptive technologies, with Power winning for its patient-matching platform. The event aimed to improve clinical trials for faster, more efficient medicine delivery.

CoherentMI's report on the Clinical Trial Patient Recruitment Services Market forecasts a CAGR of 8.2% from 2024 to 2031, reaching USD 19.1 Bn. The report details market drivers, trends, key players, and regional analysis, offering insights for strategic growth.

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.